Meet the expert: Topical management of vulvar dermatoses

Lichenoid tissue eruption of the vulva associated with immune checkpoint inhibitor

“… 6 , 7 A separate publication reported that 76% of patients with cancer treatment-associated vulvar LS were refractory to topical corticosteroids with around 15% necessitating systemic therapy; however, this data was not limited to ICI. 5 Lichenoid tissue eruptions resembling ELP of the vulva have not previously been reported with ICIs to our knowledge. The current patient’s underlying LS and subsequent development of oral and cutaneous LP suggest that ICI triggers ELP in a predisposed individual.…”

“…By removing the inhibition of CTLA-4 and PD-1 on self-reactive T cells, autoimmune disease may arise or worsen during treatment with ICIs. 5 Inflammatory vulvar dermatoses associated with ICIs, however, are rarely reported. The first genital lichenoid tissue eruption of the vulva associated with ICI was a case of LS reported in 2016.…”